Form 8-K - Current report:
SEC Accession No. 0001493152-24-040276
Filing Date
2024-10-07
Accepted
2024-10-07 16:05:30
Documents
15
Period of Report
2024-10-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44789
2 ex10-1.htm EX-10.1 44053
3 ex99-1.htm EX-99.1 21148
  Complete submission text file 0001493152-24-040276.txt   302216

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tnfa-20241001.xsd EX-101.SCH 3018
5 XBRL LABEL FILE tnfa-20241001_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE tnfa-20241001_pre.xml EX-101.PRE 24167
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3697
Mailing Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205 856-848-8698
TNF Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36268 | Film No.: 241357841
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)